{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:15:14Z","timestamp":1788340514738,"version":"build-2803163510"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although daily oral antiretroviral therapy (ART) is effective, pill burden, adherence challenges, stigma, and confidentiality concerns remain problematic for people living with HIV (PLHIV). Long-acting injectable ART (LAI-ART) is a promising alternative; however, data from the Middle East and North Africa (MENA) are limited. This study assessed PLHIV interest in LAI-ART and explored perceived benefits and barriers to implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicenter cross-sectional survey was conducted from October 2023 to December 2024 among PLHIV in Egypt, the Kingdom of Saudi Arabia, and Oman who were receiving or had previously received ART.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1010 respondents, 88.7% expressed an interest in LAI-ART. Reported benefits included avoiding daily pills (91.1%), improved adherence (87.8%), enhanced confidentiality (86.7%), support for treatment adherence with comorbidities (88.3%), and reduced missed doses (74.5%). Reported barriers included injection pain (31.9%), difficulty scheduling travel within injection windows (30.6%), and frequent clinic visits (23.3%) to receive the injection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>High interest in LAI-ART suggests readiness for adoption in the MENA region. Successful implementation requires addressing injection-related concerns through patient education, ensuring trained healthcare personnel, and adopting flexible scheduling to accommodate travel and lifestyle needs, while leveraging confidentiality benefits to mitigate HIV-related stigma and support adherence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/trstmh\/trag058","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:12:19Z","timestamp":1777637539000},"page":"948-957","source":"Crossref","is-referenced-by-count":0,"title":["Long-acting antiretroviral injections: perspectives of people living with HIV in three Middle East countries"],"prefix":"10.1093","volume":"120","author":[{"given":"Rahma","family":"Mohamed","sequence":"first","affiliation":[{"name":"Cairo University Cairo University Hospitals HIV Clinic, Endemic Medicine Department, , Cairo 12613 ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6780-0932","authenticated-orcid":false,"given":"Salma M A","family":"Mansour","sequence":"additional","affiliation":[{"name":"Egyptian Patent Office, Egyptian Intellectual Propriety Authority , Cairo 11516 ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Fahmy","sequence":"additional","affiliation":[{"name":"Cairo University Cairo University Hospitals HIV Clinic, Endemic Medicine Department, , Cairo 12613 ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Cordie","sequence":"additional","affiliation":[{"name":"Cairo University Cairo University Hospitals HIV Clinic, Endemic Medicine Department, , Cairo 12613 ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roaa Al","family":"Osaimi","sequence":"additional","affiliation":[{"name":"East Jeddah Hospital Infectious Diseases Department, , Jeddah 22253, KSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5107-921X","authenticated-orcid":false,"given":"Faryal","family":"Khamis","sequence":"additional","affiliation":[{"name":"Royal Hospital Adult Infectious Diseases Department, , Muscat 111 ,","place":["Oman"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batool","family":"Ali","sequence":"additional","affiliation":[{"name":"East Jeddah Hospital Infectious Diseases Department, , Jeddah 22253, KSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renad Al","family":"Ghurybi","sequence":"additional","affiliation":[{"name":"East Jeddah Hospital Infectious Diseases Department, , Jeddah 22253, KSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaleela Al","family":"Namani","sequence":"additional","affiliation":[{"name":"Royal Hospital Department of Nursing, , Muscat 111 ,","place":["Oman"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muna","family":"Ba\u2019Omar","sequence":"additional","affiliation":[{"name":"Royal Hospital Adult Infectious Diseases Department, , Muscat 111 ,","place":["Oman"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amany Ahmed","family":"Salem","sequence":"additional","affiliation":[{"name":"Cairo University Public Health and Community Medicine Department, , Cairo, Giza 12613 ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Ali","family":"Kabbash","sequence":"additional","affiliation":[{"name":"Tanta University Public Health and Community Medicine Department, Faculty of Medicine, , Tanta 31527 ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"2026090204263949500_bib1","author":"UNAIDS","year":"2024"},{"key":"2026090204263949500_bib2","author":"UNAIDS","year":"2021"},{"key":"2026090204263949500_bib3","volume-title":"Regional Profiles: Middle East And North Africa","author":"UNAIDS","year":"2021"},{"key":"2026090204263949500_bib4","volume-title":"FDA Approves First Extended-Release, Injectable Drug Regimen for Adults Living with HIV","author":"FDA News Release","year":"2021"},{"key":"2026090204263949500_bib5","volume-title":"Highlights Of Prescribing Information: Cabenuva","author":"ViiV Healthcare","year":"2021"},{"key":"2026090204263949500_bib6","first-page":"ciae579","article-title":"Real world virologic outcomes in patients with elevated body mass index receiving long acting cabotegravir\/rilpivirine","author":"Maguire","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026090204263949500_bib7","first-page":"1","article-title":"Long-acting injectable antiretroviral therapy: will it change the future of HIV treatment?","volume":"10","author":"Brizzi","year":"2023","journal-title":"Ther Adv Infect Dis"},{"key":"2026090204263949500_bib8","article-title":"Monthly long-acting cabotegravir and rilpivirine is non-inferior to oral ART as maintenance therapy for HIV-1 infection: week 48 pooled analysis from the phase 3 ATLAS and FLAIR studies","volume-title":"10th IAS Conference on HIV Science","author":"Overton","year":"2019"},{"key":"2026090204263949500_bib9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s10461-024-04490-0","article-title":"Improvements in patient-reported outcomes after 12 months of maintenance therapy with cabotegravir + rilpivirine long-acting compared with bictegravir\/emtricitabine\/tenofovir alafenamide in the Phase 3b SOLAR study","volume":"29","author":"Mussini","year":"2025","journal-title":"AIDS Behav"},{"key":"2026090204263949500_bib10","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/QAI.0000000000003448","article-title":"Safety and effectiveness from the cabotegravir and rilpivirine implementation study in European Locations study: Phase 3b Hybrid Type III implementation study integrating cabotegravir + rilpivirine long-acting into European clinical settings","volume":"96","author":"Jonsson-Oldenbttel","year":"2024","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026090204263949500_bib11","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/S2352-3018(23)00300-4","article-title":"Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017 [MOCHA] study): a phase1\/2, open-label, noncomparative, dose-finding trial","volume":"11","author":"Gaur","year":"2024","journal-title":"Lancet HIV"},{"key":"2026090204263949500_bib12","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1089\/aid.2023.0108","article-title":"Favorable virological outcome, characteristics of injection site reactions, decrease in renal function biomarkers in Asian people with HIV receiving long-acting cabotegravir plus rilpivirine","volume":"40","author":"Adachi","year":"2024","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2026090204263949500_bib13","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1007\/s40121-023-00890-2","article-title":"Cabotegravir + rilpivirine long-acting injections for HIV treatment in the US: real world data from the OPERA cohort","volume":"12","author":"Sension","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2026090204263949500_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1002183","article-title":"Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis","volume":"13","author":"Shubber","year":"2016","journal-title":"PLoS Med"},{"key":"2026090204263949500_bib15","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1473-3099(24)00289-5","article-title":"Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial","volume":"24","author":"Kityo","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026090204263949500_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-024-09748-5","article-title":"Long-acting injectable antiretroviral treatment: experiences of people with HIV and their healthcare providers in Uganda","volume":"24","author":"Zakumumpa","year":"2024","journal-title":"BMC Infect Dis"},{"key":"2026090204263949500_bib17","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1089\/apc.2023.0017","article-title":"High acceptability and perceived feasibility of long-acting injectable antiretroviral treatment among people living with HIV who are viremic and health workers in Uganda","volume":"37","author":"Kennedy","year":"2023","journal-title":"AIDS Patient Care STDs"},{"key":"2026090204263949500_bib18","first-page":"703","article-title":"Implementing long-acting injectable antiretroviral treatments in Senegal: issues, challenges and conditions for introducing them. Qualitative study with healthcare providers and patients","volume":"36","author":"Carillon","year":"2024","journal-title":"AIDS Care\u2014Psychol Socio-Medical Asp AIDS\/HIV"},{"key":"2026090204263949500_bib19","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/sextrans-2020-054648","article-title":"Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries","volume":"97","author":"Akinwunmi","year":"2021","journal-title":"Sex Transm Infect"},{"key":"2026090204263949500_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0000000000030052","article-title":"Long-acting drugs: people\u2019s expectations and physicians\u2019 preparedness. Are we readying to manage it? An Italian survey","volume":"101","author":"Celesia","year":"2022","journal-title":"Medicine"},{"key":"2026090204263949500_bib21","first-page":"1220","article-title":"Barriers to access to care reported by women living with HIV across 27 countries","volume":"27","author":"Johnson","year":"2015","journal-title":"AIDS Care\u2014Psychol Socio-Medical Asp AIDS\/HIV"},{"key":"2026090204263949500_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7448\/IAS.18.1.20084","article-title":"Women and HIV: the urgent need for more research and policy attention in the Middle East and North Africa region","volume":"18","author":"DeJong","year":"2015","journal-title":"J Int AIDS Soc"},{"key":"2026090204263949500_bib23","first-page":"536","article-title":"Preferences of people living with HIV for injectable and oral antiretroviral treatment in the Netherlands: a discrete choice experiment","volume":"36","author":"Kremer","year":"2024","journal-title":"AIDS Care\u2014Psychol Socio-Medical Asp AIDS\/HIV"},{"key":"2026090204263949500_bib24","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1007\/s10461-024-04423-x","article-title":"Engagement in care, awareness, and interest in long-acting injectable anti-retroviral therapy","volume":"28","author":"Stout","year":"2024","journal-title":"AIDS Behav"},{"key":"2026090204263949500_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43058-024-00631-7","article-title":"Patient and clinic staff perspectives on the implementation of a long-acting injectable antiretroviral therapy program in an urban safety-net health system","volume":"5","author":"Agovi","year":"2024","journal-title":"Implement Sci Commun"},{"key":"2026090204263949500_bib26","first-page":"259","article-title":"Preference for long-acting injectable for ART and PrEP among people with and without HIV: a cross-sectional study in Argentina","volume":"9","author":"Soiza","year":"2018","journal-title":"Ther Adv Vaccines"},{"key":"2026090204263949500_bib27","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1016\/S2666-5247(22)00009-X","article-title":"Long-acting injectable ART for HIV: a (cautious) step forward","volume":"3","author":"Venkatesan","year":"2022","journal-title":"Lancet Microbe"},{"key":"2026090204263949500_bib28","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/JNC.0000000000000386","article-title":"Injectable long-acting cabotegravirrilpivirine therapy for people living with HIV\/AIDS: addressing implementation barriers from the start","volume":"34","author":"Pinto","year":"2023","journal-title":"J Assoc Nurses AIDS Care"},{"key":"2026090204263949500_bib29","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/QAI.0000000000003421","article-title":"Identifying implementation determinants and strategies for long-acting injectable cabotegravir-rilpivirine in people with HIV who are virally unsuppressed","volume":"96","author":"Hickey","year":"2024","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026090204263949500_bib30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jia2.26282","article-title":"Long-acting injectable ART to advance health equity: a descriptive analysis of US clinic perspectives on barriers, needed support and programme goals for implementation from applications to the ALAI UP Project","volume":"27","author":"Nguyen","year":"2024","journal-title":"J Int AIDS Soc"},{"key":"2026090204263949500_bib31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1089\/apc.2024.0067","article-title":"Perspectives among health care providers and people with HIV on the implementation of long-acting injectable cabotegravir\/rilpivirine for antiretroviral therapy in Florida","volume":"38","author":"Fisk-Hoffman","year":"2024","journal-title":"AIDS Patient Care STDs"},{"key":"2026090204263949500_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0262926","article-title":"Perspectives on preparing for long-acting injectable treatment for HIV among consumer, clinical and nonclinical stakeholders: a qualitative study exploring the anticipated challenges and opportunities for implementation in Los Angeles County","volume":"17","author":"Jolayemi","year":"2022","journal-title":"PLoS One"},{"key":"2026090204263949500_bib33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s43058-024-00631-7","article-title":"Patient and clinic staff perspectives on the implementation of a long-acting injectable antiretroviral therapy program in an urban safety-net health system","volume":"5","author":"Agovi","year":"2024","journal-title":"Implement Sci Commun"},{"key":"2026090204263949500_bib34","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1089\/apc.2018.0198","article-title":"Long-acting injectable antiretroviral treatment acceptability and preferences: a qualitative study among US providers, adults living with HIV, and parents of youth living with HIV","volume":"33","author":"Simoni","year":"2019","journal-title":"AIDS Patient Care STDs"},{"key":"2026090204263949500_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43058-023-00506-3","article-title":"Assessing readiness to implement long-acting injectable HIV antiretroviral therapy: provider and staff perspectives","volume":"4","author":"Koester","year":"2023","journal-title":"Implement Sci Commun"},{"key":"2026090204263949500_bib36","doi-asserted-by":"crossref","first-page":"102979","DOI":"10.1016\/j.japh.2025.102979","article-title":"Exploring workflows for long-acting antiretroviral therapy administration in community pharmacies","author":"Clinard","year":"2025","journal-title":"J Am Pharm Assoc"},{"key":"2026090204263949500_bib37","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/phar.2922","article-title":"Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1: endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists","volume":"44","author":"Sherman","year":"2024","journal-title":"Pharmacotherapy"}],"container-title":["Transactions of The Royal Society of Tropical Medicine and Hygiene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/trstmh\/article-pdf\/120\/9\/948\/68352300\/trag058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/trstmh\/article-pdf\/120\/9\/948\/68352300\/trag058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:26:53Z","timestamp":1788337613000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/trstmh\/article\/120\/9\/948\/8688828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5,21]]},"published-print":{"date-parts":[[2026,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/trstmh\/trag058","relation":{},"ISSN":["0035-9203","1878-3503"],"issn-type":[{"value":"0035-9203","type":"print"},{"value":"1878-3503","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,5,21]]}}}